Semaglutide and Bowel Obstruction: Understanding the Risk

*This article is for informational purposes only. It is not medical advice. Compounded semaglutide is not FDA-approved. Consult a licensed healthcare provider before starting any medication or making changes to your treatment plan. If you experience severe abdominal pain, persistent vomiting, or inability to pass stool or gas, seek immediate medical care.*

---

If you are taking or considering semaglutide, you may have come across reports linking GLP-1 medications to bowel obstruction or a condition called ileus. That is worth taking seriously, and you deserve a clear answer rather than either false reassurance or unnecessary alarm.

Here is the core of what the evidence shows: semaglutide significantly slows gastric emptying as part of how it works. For most people, this translates to common GI side effects like nausea and constipation. In rare cases, the slowdown of gut motility can progress further, to a state called ileus (where the bowel essentially stops moving) or to mechanical bowel obstruction. The absolute risk appears to be low in the general population, but it is not zero, and certain factors raise that risk meaningfully.

This article covers the mechanism, the evidence, who is most at risk, and exactly what symptoms require immediate care.

---

What Is Bowel Obstruction and Ileus?

These two conditions are related but distinct.

Ileus is a functional problem: the bowel stops moving normally, not because anything is physically blocking it, but because the muscular contractions that push food forward have slowed to a halt. The gut contents back up, causing bloating, pain, and inability to pass stool or gas. Ileus can occur after abdominal surgery (which is common) or as a result of medications, infection, or metabolic disturbances.

Bowel obstruction typically involves a physical blockage. The intestinal passage is narrowed or blocked entirely, either by scar tissue (adhesions), hernia, tumor, or sometimes by impacted food or material when gut motility is already slow. Both conditions cause similar symptoms: abdominal distension, pain, nausea, vomiting, and inability to have a bowel movement.

Both can range from mild to life-threatening. Severe cases require hospitalization and, in some situations, surgery.

---

How Semaglutide Affects Gut Motility

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone naturally released by the gut after eating. It signals the brain to reduce appetite, prompts the pancreas to release insulin, and importantly, slows the rate at which food leaves the stomach (a process called gastric emptying).

Slowing gastric emptying is partly why semaglutide is so effective: food sits in the stomach longer, prolonging the feeling of fullness and reducing overall intake. This effect extends through the entire GI tract. Gut transit time increases, meaning food moves more slowly from stomach to small intestine to colon.

For most people, this translates to manageable side effects: nausea (particularly during dose escalation), constipation, and a general sense of GI sluggishness. These typically improve as the body adjusts.

For a subset of people, however, the degree of gut motility suppression is more significant. In those cases, the slowdown can progress toward gastroparesis (severely delayed stomach emptying) or contribute to the conditions that precede ileus and obstruction.

The FDA prescribing information for semaglutide explicitly notes ileus as a reported adverse event and instructs providers to monitor for GI symptoms during treatment.

---

What the Evidence Shows

A landmark 2023 study published in *JAMA* by Sodhi, Rezaeianzadeh, Kezouh, and Etminan examined GI adverse events in people using GLP-1 receptor agonists for weight loss compared to those using other weight-loss medications. The researchers found that GLP-1 receptor agonist users had significantly higher rates of several GI complications, including gastroparesis, pancreatitis, and biliary disease, compared to the comparator group. [1]

A 2025 systematic review and meta-analysis published in *Expert Opinion on Drug Safety* analyzed 14 studies covering more than 550,000 participants and examined the relationship between GLP-1 receptor agonist use and bowel obstruction or ileus specifically. The pooled analysis did not find a statistically significant overall increase in bowel obstruction or ileus risk across GLP-1 agonists as a class (OR 1.95, 95% CI 0.43 to 8.79). However, the studies showed high variability, and a subgroup analysis found that liraglutide was associated with a significantly elevated risk. Semaglutide did not show the same signal in that subgroup analysis. [2]

Several published case reports document bowel obstruction or severe ileus in patients on semaglutide. A 2026 case in *Cureus* described a 59-year-old woman on semaglutide who developed small bowel obstruction from severe ileus, complicated by acute kidney injury requiring dialysis. [3] A 2025 case report in *Endocrinology, Diabetes and Metabolic Case Reports* described a patient who developed subocclusive ileus following unsupervised, off-label high-dose semaglutide use. [4]

What this body of evidence supports: the risk appears to be real, rare in the general population of appropriately dosed patients under medical supervision, and concentrated among people with specific risk factors. It is not a reason to categorically avoid semaglutide, but it is a reason to know who is at elevated risk and what to watch for.

---

Who Is at Higher Risk?

The following factors increase the risk that semaglutide's GI effects will progress beyond routine side effects:

Prior abdominal surgery. Abdominal and pelvic surgeries leave scar tissue (adhesions) that can narrow or partially obstruct the bowel. When gut motility is already slowed by semaglutide, adhesions that were never previously symptomatic can become a genuine obstruction risk. If you have had any abdominal surgery, including appendectomy, Caesarean section, bowel surgery, or hernia repair, discuss this history explicitly with your prescribing provider.

Existing gastroparesis. Gastroparesis is a condition in which the stomach empties abnormally slowly, most commonly as a complication of diabetes. It is already associated with impaired gut motility. Adding a medication that further slows gastric emptying can worsen gastroparesis significantly, sometimes to the point of severe symptoms requiring hospitalization. People with known or suspected gastroparesis need a careful provider conversation before starting semaglutide.

Poorly controlled diabetes. Diabetic autonomic neuropathy, a complication of long-standing or poorly controlled diabetes, damages the nerves that regulate gut motility. This creates a baseline vulnerability that semaglutide's motility effects compound.

Sudden major dietary changes. Some case reports involve patients who consumed unusually large amounts of high-fiber, slow-digesting foods while on semaglutide. When gastric emptying is already slow, a bolus of very fibrous material can contribute to a functional blockage. A sudden shift to a very high-fiber diet at the start of semaglutide therapy can be problematic for this reason.

High or escalating doses without medical supervision. Several case reports involve off-label or self-administered semaglutide use at doses beyond standard protocols. The motility-suppressing effects appear to be dose-dependent. Using semaglutide outside of a supervised medical context increases this risk meaningfully.

---

Constipation vs. Obstruction: Knowing the Difference

Constipation is one of the most common GI side effects of semaglutide. You can read more about managing it in our guide on [managing GLP-1 side effects](/resources/managing-glp1-side-effects). Constipation and bowel obstruction are not the same thing, but constipation that is severe or prolonged can, in the right circumstances, progress. The distinction matters because the response is very different.

Constipation on semaglutide typically involves infrequent, difficult bowel movements. It responds to hydration, dietary fiber (introduced gradually), physical activity, and sometimes over-the-counter agents like polyethylene glycol. It is uncomfortable but not dangerous for most people.

Warning signs that suggest something more serious:

• Severe, worsening abdominal pain, not mild cramping
• Significant abdominal distension or bloating that does not improve
• Inability to pass any stool or gas for an extended period (more than 24 to 48 hours, especially if accompanied by pain)
• Nausea and vomiting that do not resolve, particularly vomiting of fecal-smelling material
• A hard, rigid, or very tender abdomen when you press on it

If you are unsure whether your symptoms are constipation or something more serious, the answer is always: contact your provider. Do not attempt to manage possible obstruction at home.

---

Is the Risk the Same With Compounded Semaglutide?

This is a fair question. Compounded semaglutide contains the same active molecule (semaglutide) as FDA-approved Ozempic and Wegovy and works through the same GLP-1 receptor mechanism. The mechanism driving the motility effects is the same.

However, compounded semaglutide is not FDA-approved. It has not been independently evaluated by the FDA for safety, efficacy, purity, or potency. Compounding pharmacies operate under different oversight frameworks than FDA-approved drug manufacturers. Dose accuracy and consistency, which matter significantly for a dose-dependent motility effect, may not be as tightly controlled.

The case reports of bowel obstruction and ileus in patients using semaglutide include cases involving off-label dosing and unsupervised use, which is more common in compounded markets. If you use compounded semaglutide, provider supervision is not optional; it is particularly important.

You can learn more about compounded semaglutide and how it differs from branded products in our detailed guide: [Compounded Semaglutide: What It Is and How It Differs](/resources/compounded-semaglutide-what-it-is).

For a broader overview of common GI side effects and how to manage them, see our article on [semaglutide side effects: what to expect](/resources/semaglutide-side-effects-what-to-expect).

---

When to Stop the Medication and Call Your Provider

If you develop any of the warning symptoms listed above, stop your next dose and seek care immediately. Do not wait for your regular follow-up appointment.

Tell the provider or emergency team that you are taking semaglutide, and share the dose and how long you have been on it. This context affects how your symptoms are evaluated.

If ileus or obstruction is confirmed, your provider will discontinue semaglutide as part of your treatment.

---

The Bottom Line

Semaglutide slows gastric emptying by design. For most people under appropriate medical supervision, this produces manageable GI side effects that improve with time and dose titration. In rare cases, particularly among people with prior abdominal surgery, underlying gastroparesis, or certain other risk factors, the gut slowdown can progress to ileus or bowel obstruction, which requires immediate medical attention.

The risk is not a reason to avoid semaglutide if it is appropriate for you. It is a reason to know your own risk factors, work with a qualified provider, pay attention to your body, and know which symptoms require urgent care rather than a wait-and-see approach.

If you want to understand whether semaglutide is right for your situation, starting with a licensed provider evaluation is the appropriate first step.

[Start your assessment](/weight-loss)

---

*This article is for informational purposes only. It does not constitute medical advice. Compounded semaglutide is not FDA-approved and has not been independently evaluated by the FDA for safety, efficacy, or quality. Prescriva operates as a Management Services Organization (MSO) and does not directly employ or supervise clinicians. All prescribing decisions are made by independent licensed healthcare providers. Individual results vary. Consult your provider before starting or stopping any medication.*

Brand Disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Prescriva is not affiliated with, endorsed by, or sponsored by Novo Nordisk. References to FDA-approved branded semaglutide are made for educational and regulatory-context purposes only. Compounded semaglutide is a separate product not evaluated or approved by the FDA, and clinical trial data from FDA-approved branded formulations does not establish the safety or efficacy of compounded preparations.

---

References

1. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. *JAMA.* 2023;330(18):1795-1797. PMID: 37796527

1. Alfehaid L, Alyami M, Almohareb S, Alshaya O, Almutairi A. Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 2025. PMID: 39964295

1. Rallabandi S, Sharma M, Kosuru K, Kashyap R. A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis. *Cureus.* 2026;18(2):e104376. PMID: 41913883

1. Nikolaeva A, Vandeputte M. Subocclusive ileus following off-label high-dose semaglutide use. *Endocrinol Diabetes Metab Case Rep.* 2025;2025(4):e250081. PMID: 41294925

1. U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. Accessed 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s021lbl.pdf

See Also

• [Semaglutide Side Effects: What to Expect and How to Manage Them](/resources/semaglutide-side-effects-what-to-expect)
• [Compounded Semaglutide: What It Is and How It Differs](/resources/compounded-semaglutide-what-it-is)
• [Managing GLP-1 Side Effects](/resources/managing-glp1-side-effects)